ArticleAmerican journal of translational research2021
Analysis and evaluation of DRCOP scheme based on polyethylene glycol liposome doxorubicin in patients with diffuse large B-cell lymphoma.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
- Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma.Mini reviews in medicinal chemistry · 2024Review
- Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate and study the therapeutic effect of DRCOP regimen based on polyethylene glycol liposome doxorubicin (PLD) on patients with diffuse large B cell lymphoma (DLBCL).
methodsA retrospective analysis was conducted on 80 patients with DLBCL admitted to our hospital from June 2016 to June 2017, and the patients were equally and randomly divided into the experimental and the control group. Patients in the experimental group were treated with the DRCOP regimen based on PLD, and the patients in the control group were treated with the traditional DRCOP regimen. The short-term clinical effects, adverse reactions, the effective rate of treatment, survival rates and cardiotoxicity of patients in the two groups were compared. The three-year survival status of the two groups was compared.
resultsIn the experimental group, 21 cases (52.50%) of complete remission (CR) with a total effective rate of 82.50% were noticed, while 13 patients (32.50%) displayed a total effective rate of 57.50% in the control group, and the difference between the data of the two groups was statistically significant. A significant reduction of cardiotoxicity such as myocardial infarction, myocardial injury and abnormal electrocardiogram in the experimental group compared with the control group was detected (
conclusionDRCOP regimen based on PLD has a better clinical treatment effect for patients with DLBCL, which can significantly reduce the cardiotoxicity caused by chemotherapy, with higher safety. Thus, it can effectively improve the treatment efficiency of patients and reduce the occurrence of adverse reactions.
Indexed as
Identifiers
34150131PMC8205818W3173697258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.